This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eppes;, S. C.
Right arrow Articles by Weisman, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eppes;, S. C.
Right arrow Articles by Weisman, L. E.

PEDIATRICS Vol. 103 No. 2 February 1999, pp. 534-535

Questions About Palivizumab (Synagis)

The first 20% of the full text of this article appears below.

To the Editor.

A humanized monoclonal antibody designed for the prevention of serious disease attributable to respiratory syncytial virus (RSV) has recently been approved by the Food and Drug Administration (FDA). Palivizumab, manufactured by MedImmune, Inc (Gaithersburg, MD) and marketed as Synagis, is indicated for pediatric patients who are at high risk for severe infection with RSV. Because it is highly concentrated, it can be administered as a single monthly intramuscular injection, a significant advantage over RSV immune globulin, which requires intravenous access and is logistically challenging to administer.

The results of the IMpact-RSV study,1 which provided the basis for FDA approval, included the finding that use . . . [Full Text of this Article]


This article has been cited by other articles:


Home page
 Arch Pediatr Adolesc MedHome page
S. Kamal-Bahl, J. Doshi, and J. Campbell
Economic Analyses of Respiratory Syncytial Virus Immunoprophylaxis in High-Risk Infants: A Systematic Review
Arch Pediatr Adolesc Med, October 1, 2002; 156(10): 1034 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 AAP Grand RoundsHome page
G. M. Onady
Effectiveness of Palivizumab Therapy for RSV
AAP Grand Rounds, April 1, 2001; 5(4): 37 - 38.
[Full Text] [PDF]

Home page
 PediatricsHome page
G. Suresh;, W. T. Zempsky, N. L. Schechter;, J. L. Fox;, E. M. Connor, D. Carlin, F. H. Top, J. MD, and L. E. Weisman
IMpact-RSV Study Group Report
Pediatrics, October 1, 1999; 104(4): 993 - 994.
[Full Text]